利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

192 条记录 (耗时 0.025 秒)

    PRIMING OF CANCER CELLS WITH LOW DOSE NALTREXONE
    113.
    发明公开
    PRIMING OF CANCER CELLS WITH LOW DOSE NALTREXONE 审中-公开
    PRIMING VON KREBSZELLEN MIT NIEDRIG DOSIERTEM NALTREXON

    公开(公告)号：EP3151831A1

    公开(公告)日：2017-04-12

    申请号：EP15730526.9

    申请日：2015-06-09

    申请人： Cancer Vaccine Institute

    发明人： DALGLEISH, Angus ,  LIU, Wai

    IPC分类号： A61K31/436 ,  A61P35/00

    CPC分类号： A61K31/485 ,  A61K31/282 ,  A61K31/436 ,  A61K31/664 ,  A61K31/7068 ,  A61K45/06 ,  G01N33/57484 ,  G01N2333/4703 ,  G01N2510/00

    摘要： The present invention provides a pharmaceutical composition comprising naltrexone or an analogue thereof for use in the treatment of a subject having a tumour/cancer; wherein the naltrexone or the analogue thereof is to be administered to the subject in a first treatment phase, followed by a recovery phase; wherein, following the recovery phase, a small molecule signalling inhibitor selected from the group consisting of PI3-kinase inhibitors, AKT inhibitors, taxanes, antimetabolites, alkylating agents and cell cycle inhibitors is to be administered to the subject in a second treatment phase; the recovery phase being characterised by the absence of administration of the naltrexone or the analogue thereof and the small molecule signalling inhibitor. Also envisaged are a diagnostic test to assess the response of a subject to the first treatment phase, an in vitro method of testing the efficacy of a small molecule signalling inhibitor when for use in combination with naltrexone, and the use of naltrexone in such a method when in vivo.

    摘要翻译： 本发明提供包含纳曲酮或其类似物的药物组合物，用于治疗患有肿瘤/癌症的受试者; 其中纳曲酮或其类似物将在第一治疗阶段施用于受试者，随后是恢复期; 其中，在恢复阶段之后，在第二处理阶段向受试者施用选自PI3-激酶抑制剂，AKT抑制剂，紫杉烷类，抗代谢物，烷化剂和细胞周期抑制剂的小分子信号传导抑制剂; 恢复期的特征在于不给予纳曲酮或其类似物和小分子信号传导抑制剂。 还设想了用于评估受试者对第一治疗阶段的反应的诊断测试，用于与纳曲酮组合使用时测试小分子信号传导抑制剂的功效的体外方法，以及在这种方法中使用纳曲酮 当体内。

    COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES
    115.
    发明公开
    COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES 有权
    茉莉花EN EN INF ON ON ON ON TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN TEN

    公开(公告)号：EP3144008A1

    公开(公告)日：2017-03-22

    申请号：EP16190858.7

    申请日：2013-03-15

    申请人： The John Hopkins University

    发明人： FUCHS, Ephraim Joseph ,  SYMONS, Heather Jill ,  SWINNEN, Lode

    IPC分类号： A61K38/00 ,  A61P7/00 ,  A61P35/00 ,  C12N5/078

    CPC分类号： A61K35/17 ,  A61K31/664 ,  A61K45/06 ,  C12N5/0087 ,  C12N5/0638 ,  Y02A50/463

    摘要： The invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host.

    摘要翻译： 本发明提供用于给予同种异体淋巴细胞作为内源性，肿瘤反应性CD8 + T细胞的CD4 + T细胞帮助的外源性源的方法和组合物。 来自供体淋巴细胞输注的CD8 + T细胞的消耗减少了持续移植和移植物抗宿主病的风险。 从输注的群体中去除调节性T细胞可增加非调节性T细胞为抗肿瘤免疫的内源性作用因子提供帮助的能力。 同种异体T细胞治疗通常在同种异体干细胞移植的背景下给出，其中患者接受高度免疫抑制调节，随后输注含有未选择的成熟T细胞群体的干细胞移植物。 在这里描述的治疗中，移植物被工程化以最小化持续供体细胞移植的可能性，并且抗肿瘤效应T细胞来源于宿主。